Ian Gibbons (biochemist)

As chief scientist within Theranos, Gibbons often gave the staff informal lectures on biochemistry and the science of blood testing. To ensure product success, Gibbons insisted that blood test results from Theranos developmental devices match benchmark results of competitors' commercial analyzers. Theranos' devices often became a source of frustration for Gibbons, as they differed, sometimes significantly, from the benchmarks. His high standards became a source of friction with Theranos engineers and senior management. Senior management warned employees who questioned the accuracy of the technology.[4] As a result of his desperation, Gibbons confided to his wife that "nothing at Theranos is working".[2] Holmes' practice of discouraging communication between departments also troubled Gibbons. The reason given for such information siloing was that the company was operating in stealth mode to protect its trade secrets.[4] However, it prevented effective problem solving and pursuance of common goals between employees.

With an insider perspective, Gibbons knew of Holmes' lies to employees and outsiders about Theranos' technology and readiness, as well as false demonstrations to clients. Thus, Gibbons no longer trusted Holmes. However, he continued to struggle to make the flawed Theranos technology catch up to the hype.[6][2]

In the fall of 2010, Holmes was alerted of Gibbons' complaints and frustrations, and he was fired. Several of his colleagues lobbied on his behalf, and he was quickly rehired; with reduced responsibilities, as a technical consultant to the chemistry group he had formerly headed.[4]

Inventor-entrepreneur Richard Fuisz was a former friend and next-door neighbor of the Holmes family. The two families had fallen out, and Fuisz's offer to help Holmes with her invention had been declined.[7] Fuisz studied the information that was publicly available regarding the Theranos technology, and identified a desirable feature that was not discussed in the Theranos patents. He filed for his own patent on the feature – a physician-alert mechanism that could be embedded in the testing device, something that would interfere with Theranos' ability to market its devices for use in consumer homes, because it would be necessary to obtain a license to use his patent if the devices included a physician alert mechanism, and this was an obviously desirable feature (to the degree that it was arguably necessary for market viability). When Theranos learned of the filing, it sued Fuisz, alleging theft of its confidential information.[4][2]

Gibbons was named as co-inventor with Holmes on many Theranos patents. When researching his defense to the Theranos lawsuit, Fuisz noticed similarities between Gibbons' patents at Biotrack and recent Theranos patents. Suspecting improper reuse of past work or improper identification of Holmes as a co-inventor, he added Gibbons' name to his list of witnesses to be deposed.

When Gibbons learned that he would be subpoenaed to testify, he became nervous and depressed. He wanted to avoid being deposed, afraid his job depended on his testimony. Gibbons believed that if he told the truth, he would lose his job and have limited future job prospects due to his age.[2][8]